Skip to main content

Skyrizi (Risankizumab) & Lymphoma

    Basic Details
    Status
    Ongoing
    Last Updated
    Thursday, December 7, 2023
    Original Posting Date
    Health Outcome(s)
    lymphoma
    Purpose
    Drug and Outcome Analysis
    Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
    Yes